Millipore Sigma Vibrant Logo

504314 Bortezomib - CAS 179324-69-7 - Calbiochem

Bortezomib, CAS 179324-69-7, is a cell-permeable, selective, slowly reversible inhibitor of 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity.

Bortezomib - CAS 179324-69-7 - Calbiochem: Ficha de dados de segurança do material (FDSM) ou ficha de segurança do material (FSM), certificado de análise (CA) e certificado de qualidade (CQ), dossiês e outros documentos disponíveis.

Sinônimos: (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu

Primary Target: 20S proteasome
View Products on Sigmaaldrich.com
504314
Ver preços e disponibilidade

Panorama geral

Replacement Information

Tabela com principais espec.

CAS #Empirical Formula
179324-69-7C₁₉H₂₅BN₄O₄

Preço e Disponibilidade

Número de catálogo DisponibilidadeEmbalagem Qtde/Emb. Preço Quantidade
5043140001
Verificando a disponibilidade...
—
Disponibilidade limitada Disponibilidade limitada
Insira quantidade 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente
      Contact Customer Service

      		 Frasco de vidro 5 mg
      Recuperando preço...
      O preço não pôde ser recuperado
      Quantidade mínima necessária para ser múltipla de
      Maximum Quantity is
      Após finalização do pedido Mais informações
      Você salvou ()
       
      —
      Solicitar preço
      		 —
      Description
      OverviewA cell-permeable dipeptidylboronate compound that selectively inhibits 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity (kinact/Ki = 38,000, 5,700, and <100 M-1s-1, respectively, in human 20S proteasome assays using 10 µM Suc-LLVY-AMC/Cat. No. 539142, 10 µM Z-LLE-AMC/Cat. No. 539141, or 50 µM Boc-LRR-AMC as substrate) via a covalent, slowly reversible manner, displaying much reduced potency against human chymotrypsin, cathepsin G, leukocyte elastase, and thrombin (Ki = 0.32, 0.63, 2.3, and 13 µM, respectively, vs. 620 nM using rabbit muscle 20S). A widely used inhibitor both in cultures in vitro and in animals in vivo.
      Catalogue Number504314
      Brand Family Calbiochem®
      Synonyms(R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu
      References
      ReferencesDu, X.L, and Chen, Q. 2013. Acta Haematol. 129, 207.
      Tamatani, T., et al. 2013. Int. J. Oncol. 42, 935.
      Beck, P., et al. 2012. J. Biol. Chem. 393, 1101.
      Fang, H.T., et al. 2012. Proc. Natl. Acad. Sci. USA. 109, 2521.
      Chen, D., et al. 2011. Curr. Cancer Drug Targets 11, 239.
      Demo, S.D., et al. 2007. Cancer Res. 67, 6383.
      Adams, J., et al. 1999. Cancer Res. 59, 2615.
      Teicher, B.A., et al. 1999. Clin. Cancer Res. 5, 2638.
      Adams, J., et al. 1998. Bioorg. Med. Chem. Lett. 8, 333.
      Product Information
      CAS number179324-69-7
      FormOff-white solid
      Hill FormulaC₁₉H₂₅BN₄O₄
      Chemical formulaC₁₉H₂₅BN₄O₄
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationBortezomib, CAS 179324-69-7, is a cell-permeable, selective, slowly reversible inhibitor of 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity.
      Biological Information
      Primary Target20S proteasome
      Purity≥98% by LC-MS
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de catálogo GTIN
      5043140001 04055977263923

      Documentation

      Bortezomib - CAS 179324-69-7 - Calbiochem MSDS

      Título

      Ficha de Segurança de Produtos (MSDS) 

      Bortezomib - CAS 179324-69-7 - Calbiochem Certificados de análise

      TítuloNúmero do lote
      504314

      Referências

      Visão geral de referência
      Du, X.L, and Chen, Q. 2013. Acta Haematol. 129, 207.
      Tamatani, T., et al. 2013. Int. J. Oncol. 42, 935.
      Beck, P., et al. 2012. J. Biol. Chem. 393, 1101.
      Fang, H.T., et al. 2012. Proc. Natl. Acad. Sci. USA. 109, 2521.
      Chen, D., et al. 2011. Curr. Cancer Drug Targets 11, 239.
      Demo, S.D., et al. 2007. Cancer Res. 67, 6383.
      Adams, J., et al. 1999. Cancer Res. 59, 2615.
      Teicher, B.A., et al. 1999. Clin. Cancer Res. 5, 2638.
      Adams, J., et al. 1998. Bioorg. Med. Chem. Lett. 8, 333.
      Ficha de dados

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision29-March-2024 JSW
      Synonyms(R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu
      DescriptionA cell-permeable dipeptidylboronate compound that selectively inhibits 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity (kinact/Ki = 38,000, 5,700, and <100 M-1s-1, respectively, in human 20S proteasome assays using 10 µM Suc-LLVY-AMC/Cat. No. 539142, 10 µM Z-LLE-AMC/Cat. No. 539141, or 50 µM Boc-LRR-AMC as substrate; IC50 in 1 h = 7, 74, and 4,200 nM, respectively) via a covalent, slowly reversible, interaction between the nucleophilic Thr1 hydroxy group/Thr1Oγ of the catalytic β subunit and the inhibitor's electrophilic boronic moiety, displaying much reduced potency against human chymotrypsin, cathepsin G, leukocyte elastase, and thrombin (Ki = 0.32, 0.63, 2.3, and 13 µM, respectively, vs. 620 nM using rabbit muscle 20S). A widely used inhibitor both in cultures in vitro and in animals in vivo. Despite being the first proteasome inhibitor approved by FDA for clinical anticancer treatment, its therapeutic efficacy continues to be hampered by off-target effects and dose-limiting toxicity.
      FormOff-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number179324-69-7
      Chemical formulaC₁₉H₂₅BN₄O₄
      Structure formulaStructure formula
      Purity≥98% by LC-MS
      SolubilityDMSO (100 mg/ml) or Ethanol (2 mg/ml; with sonication). Use only fresh DMSO or Ethanol for reconstitution.
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesDu, X.L, and Chen, Q. 2013. Acta Haematol. 129, 207.
      Tamatani, T., et al. 2013. Int. J. Oncol. 42, 935.
      Beck, P., et al. 2012. J. Biol. Chem. 393, 1101.
      Fang, H.T., et al. 2012. Proc. Natl. Acad. Sci. USA. 109, 2521.
      Chen, D., et al. 2011. Curr. Cancer Drug Targets 11, 239.
      Demo, S.D., et al. 2007. Cancer Res. 67, 6383.
      Adams, J., et al. 1999. Cancer Res. 59, 2615.
      Teicher, B.A., et al. 1999. Clin. Cancer Res. 5, 2638.
      Adams, J., et al. 1998. Bioorg. Med. Chem. Lett. 8, 333.